MicroRNA-20a-5p inhibits the autophagy and cisplatin resistance in ovarian cancer via regulating DNMT3B-mediated DNA methylation of RBP1

Li, Hui; Lei, Yuansheng; Li, Shuangxue; Li, Feng; Lei, Jieyun

doi:10.1016/j.reprotox.2021.12.011

Cited by 25 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among multiple tumor diseases, combining autophagy blockers (e.g., miRNAs) and cytotoxic drugs is considered an effective therapeutic strategy to overcome multidrug resistance (Li et al, 2022; Wen et al, 2020). miRNA‐181a is a newly identified negative regulator of autophagy associated with cisplatin resistance in gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

circAP1M2 activates ATG9A‐associated autophagy by inhibiting miR‐1249‐3p to promote cisplatin resistance in oral squamous cell carcinoma

Wenhao,

Yali,

Shaoming

et al. 2023

Journal Cellular Physiology

View full text Add to dashboard Cite

Cisplatin (CDDP) is the first‐line chemotherapeutic agent for oral squamous cell carcinoma (OSCC). Susceptibility to drug resistance during treatment is a significant challenge in enhancing the therapeutic efficacy of OSCC. Autophagy is an essential element to guarantee the cancer cells' survival under chemo‐stress conditions. We established a cisplatin‐resistant OSCC cell line (CAL27/CDDP) and showed that circAP1M2 is a remarkably upregulated circular RNA in OSCC. Knockdown of circAP1M2 contributes to reversing cisplatin chemoresistance in vivo, while enhanced autophagic activity in cisplatin‐resistant OSCC cells contributes to chemoresistance. Mechanistically, we showed that circAP1M2 induces autophagy‐associated cisplatin resistance via the miR‐1249‐3p‐ATG9A axis in OSCC cells. This study provides insights into the specific influence of a newly identified circular RNA circAP1M2 in OSCC regarding drug abuse and the treatment of a broad range of cancers that can benefit from cisplatin.

show abstract

Section: Discussionmentioning

confidence: 99%

circAP1M2 activates ATG9A‐associated autophagy by inhibiting miR‐1249‐3p to promote cisplatin resistance in oral squamous cell carcinoma

Wenhao,

Yali,

Shaoming

et al. 2023

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Glioma growth is slowed in vitro and in vivo experiments when a DNMT1 inhibitor is given ( 36 ). Currently, there is no specific research on DNMT3B in glioma, but DNMT3B has been reported to accelerate the occurrence and progression of esophageal cancer ( 38 ), lung cancer ( 39 ), breast cancer ( 40 ), and ovarian cancer ( 41 ), implying that DNMT3B is an essential biomarker in cancer pathogenesis.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma

Zhao

Wen-hu²,

Yang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

This research aims to develop a prognostic glioma marker based on m6A/m5C/m1A genes and investigate the potential role in the tumor immune microenvironment. Data for patients with glioma were downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA). The expression of genes related to m6A/m5C/m1A was compared for normal and glioma groups. Gene Ontology and Kyoto Encyclopedia of Genes and Gene enrichment analysis of differentially expressed genes were conducted. Consistent clustering analysis was performed to obtain glioma subtypes and complete the survival analysis and immune analysis. Based on TCGA, Lasso regression analysis was used to obtain a prognostic model, and the CGGA database was used to validate the model. The model-based risk scores and the hub genes with the immune microenvironment, clinical features, and antitumor drug susceptibility were investigated. The clinical glioma tissues were collected to verify the expression of hub genes via immunohistochemistry. Twenty genes were differentially expressed, Consensus cluster analysis identified two molecular clusters. Overall survival was significantly higher in cluster 2 than in cluster 1. Immunological analysis revealed statistically significant differences in 26 immune cells and 17 immune functions between the two clusters. Enrichment analysis detected multiple meaningful pathways. We constructed a prognostic model that consists of WTAP, TRMT6, DNMT1, and DNMT3B. The high-risk and low-risk groups affected the survival prognosis and immune infiltration, which were related to grade, gender, age, and survival status. The prognostic value of the model was validated using another independent cohort CGGA. Clinical correlation and immune analysis revealed that four hub genes were associated with tumor grade, immune cells, and antitumor drug sensitivity, and WTAP was significantly associated with microsatellite instability(MSI). Immunohistochemistry confirmed the high expression of WTAP, DNMT1, and DNMT3B in tumor tissue, but the low expression of TRMT6. This study established a strong prognostic marker based on m6A/m5C/m1A methylation regulators, which can accurately predict the prognosis of patients with gliomas. m6A/m5C/m1A modification mode plays an important role in the tumor microenvironment, can provide valuable information for anti-tumor immunotherapy, and have a profound impact on the clinical characteristics.

show abstract

“…MiR-20a-5p could upregulate RBP1 expression via the downregulation of DNMT3B expression. Moreover, the elevated RBP1 had a remarkable restraining effect on autophagy by reducing the conversion of LC3-I to LC3-II (Li et al, 2022). Fus is a gene encoding an RNA-binding protein.…”

Section: Autophagy-associated Mirnas In Ovarian Cancersmentioning

confidence: 99%

Non-coding RNAs: The recently accentuated molecules in the regulation of cell autophagy for ovarian cancer pathogenesis and therapeutic response

Peng

Yan

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Autophagy is a self-recycling and conserved process, in which the senescent cytoplasmic components are degraded in cells and then recycled to maintain homeostatic balance. Emerging evidence has suggested the involvement of autophagy in oncogenesis and progression of various cancers, such as ovarian cancer (OC). Meanwhile, the non-coding RNAs (ncRNAs) frequently regulate the mRNA transcription and other functional signaling pathways in cell autophagy, displaying promising roles in human cancer pathogenesis and therapeutic response. This article mainly reviews the cutting-edge research advances about the interactions between ncRNAs and autophagy in OC. This review not only summarizes the underlying mechanisms of dynamic ncRNA-autophagy association in OC, but also discusses their prognostic implications and therapeutic biomarkers. The aim of this review was to provide a more in-depth knowledge framework exploring the ncRNA-autophagy crosstalk and highlight the promising treatment strategies for OC patients.

show abstract

MicroRNA-20a-5p inhibits the autophagy and cisplatin resistance in ovarian cancer via regulating DNMT3B-mediated DNA methylation of RBP1

Cited by 25 publications

References 26 publications

circAP1M2 activates ATG9A‐associated autophagy by inhibiting miR‐1249‐3p to promote cisplatin resistance in oral squamous cell carcinoma

circAP1M2 activates ATG9A‐associated autophagy by inhibiting miR‐1249‐3p to promote cisplatin resistance in oral squamous cell carcinoma

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma

Non-coding RNAs: The recently accentuated molecules in the regulation of cell autophagy for ovarian cancer pathogenesis and therapeutic response

Contact Info

Product

Resources

About